Heme

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Retrieved on: 
Monday, January 29, 2024
Commonwealth, Patient, Therapy, Heme, TCR, Certified Public Accountant, New England Baptist Hospital, Treasurer, Cancer, Sale, IPO, Acer, Genzyme

Mr. Amello, a senior finance executive, brings to TScan nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry.

Key Points: 
  • Mr. Amello, a senior finance executive, brings to TScan nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry.
  • “We are pleased to welcome Jason to TScan at such an exciting time as we continue to make significant progress across both our heme and solid tumor programs, with multiple important milestones on the horizon,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
  • “Jason’s corporate experience, having held several prior appointments as Chief Financial Officer, comes at the right time for us, as we continue to strategically advance our clinical-stage programs.
  • From 2000 to 2011, Mr. Amello held multiple finance leadership positions at Genzyme Corporation (acquired by Sanofi AG), including Senior Vice President and Chief Accounting Officer.

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Novartis Institute for Tropical Diseases, Research, Acute myeloid leukemia, Food, Disclosure, HIV disease progression rates, Syndrome, SITC, Annual general meeting, HCT, RIC, Society for Immunotherapy of Cancer, MDS, Neoplasm, KOL, Amgen, Cancer, Therapy, Patient, Food and Drug Administration, MAGE-C2, Acute leukemia, ASH, Heme, City, Immunotherapy, Clinical trial, Biomedical Research, PRAME, TCR, Society, HLA, Investigational New Drug, ALL, Haematopoietic system, FDA, Antigen, Trial of the century, IND, C2, Poster, Collection, Associate, AML, Vaccine, Security (finance), Pharmaceutical industry, Medical imaging, Hematology, Melanoma

WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • As of September 30, 2023, TScan Therapeutics had cash, cash equivalents, and marketable securities of $215.4 million, excluding $5.0 million of restricted cash.
  • Revenue for the third quarter ended September 30, 2023, was $3.9 million, compared to $3.4 million for the third quarter ended September 30, 2022 (2022 Quarter).
  • Research and development expenses for the third quarter ended September 30, 2023, were $22.7 million, compared to $15.0 million for the 2022 Quarter.
  • For the third quarter ended September 30, 2023, TScan Therapeutics reported a net loss of $23.0 million, compared to a net loss of $16.2 million for the 2022 Quarter.

Future diets will be short of micronutrients like iron — it’s time to consider how we feed people

Retrieved on: 
Friday, September 1, 2023
Shift, Fortification, Adoption, Pregnancy, Food, Mineral, Diet, Nut, Drink, Awareness, FSANZ, Seed, Poultry, Anemia, Red meat, Heme, Nutrient, Woman, Hope, Grain boundary strengthening, Vegetable, COVID, Government, Vitamin, Nutrient deficiency, Iron deficiency, Folate, Risk, Tea, Coffee, Food Standards Australia New Zealand, Ageing, Health, Meat, Bread, Dietary supplement, Salt, Central Africa, Iron

In New Zealand, 10.6% of women aged 15-18 and 12.1% of women aged 31-50 suffer from iron deficiency.

Key Points: 
  • In New Zealand, 10.6% of women aged 15-18 and 12.1% of women aged 31-50 suffer from iron deficiency.
  • As more people consider switching to plant-based diets, the risk of iron deficiency will likely increase.
  • We argue that fortifying foods with iron could provide a one-stop solution to bridge nutrient gaps caused by inadequate dietary intake.

Food fortification

    • Many foods in supermarket shelves, including common staples such as bread and cereals, already have added nutrients.
    • Unlike mandatory iodine and folic acid fortification of bread, there is currently no government initiative to encourage or mandate iron fortification in New Zealand.

Shift to plant-based diets

    • More consumers are opting for diets that include fewer animal-sourced foods in the hope of reducing environmental impacts and emissions.
    • Recent statistics show a 19% increase in the adoption of vegan and vegetarian diets among New Zealanders from 2018 to 2021.
    • Considering these plant-based diets for a sustainable food system must involve conversations about nutrient availability.
    • Read more:
      What to drink with dinner to get the most iron from your food (and what to avoid)

      Fortification can be a potent strategy in helping people to shift towards plant-based diets by enriching these diets with nutrients that would otherwise be lacking.

Is NZ ready for iron-fortified foods?

    • Given the importance of adequate dietary iron intake and the projected shortage in dietary iron, it is crucial to evaluate the benefits of fortification.
    • Educational interventions such as promoting awareness of iron deficiency and positive impacts of fortification may help improve consumers’ acceptance of these initiatives.
    • Mahya Tavan receives funding from the Global Dairy Platform for developing a dietary optimisation model called The iOTA Model.

IngredientWerks produces "Meaty Corn," proving it can significantly reduce the high-cost of key alternative protein ingredients, with a carbon-neutral footprint, at industrial scale

Retrieved on: 
Tuesday, July 18, 2023
Genetic distance, Taste, Heme, Fermentation, Carbon, Plant, Parity, Protein, Patent, Myoglobin, Health, Meat, Animal feed, Fine chemical

As a high-value heme protein and key animal replacement ingredient, bovine myoglobin is used to mimic the taste, texture and aroma of meat in alternative protein applications.

Key Points: 
  • As a high-value heme protein and key animal replacement ingredient, bovine myoglobin is used to mimic the taste, texture and aroma of meat in alternative protein applications.
  • Additionally, this achievement represents the first successful expression of myoglobin beef in corn, a plant-based, molecular farming application.
  • That means the production of quality, affordable, accessible and sustainable ingredients are critical in this new era of food production.
  • I'm continually amazed at the ingenuity and dedication of the IngredientWerks research team, and excited to bring this valuable solution to the industry!"

In Victory for Motif, U.S. Patent Office to Review Impossible Foods Patent

Retrieved on: 
Tuesday, June 20, 2023
Taste, Smell, Patent, IPR, Statistics, Composition, Opposition procedure before the European Patent Office, Heme, PTAB, Impossible Foods, Patent Trial and Appeal Board, Creativity, United States Patent and Trademark Office, Impossible, Cooking, Myoglobin, Flavor, European Patent Convention, Meat, Synovial joint, Dietary supplement, EU, Motif

BOSTON, June 20, 2023 /PRNewswire/ -- In a highly-anticipated ruling by its Patent Trial and Appeal Board (PTAB), the U.S. Patent and Trademark Office announced Friday it would institute inter partes review (IPR) of Patent 9,943,096 B2 claimed by Impossible Foods.

Key Points: 
  • BOSTON, June 20, 2023 /PRNewswire/ -- In a highly-anticipated ruling by its Patent Trial and Appeal Board (PTAB), the U.S. Patent and Trademark Office announced Friday it would institute inter partes review (IPR) of Patent 9,943,096 B2 claimed by Impossible Foods.
  • The ruling commences an administrative trial, expected to take about a year, on the validity of one of Impossible Foods' most important patents.
  • Motif FoodWorks petitioned for review of the patent after Impossible sued Motif in federal court last year, alleging patent infringement in using heme to create plant-based meat substitutes.
  • Late last year, the European Patent Office revoked an EU patent held by Impossible.

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

Retrieved on: 
Tuesday, March 21, 2023
Diamond, National Heart, Lung, and Blood Institute, DBA, Head, Clinical trial, CRADA, Erythropoietic porphyria, Heme, Diamond–Blackfan anemia, Bangladesh Technical Education Board, Trial of the century, Development, NHLBI, IRON, Cooperative research and development agreement, Patient, NIH, Disease, Pharmaceutical industry, Disc

The study will be conducted and funded by the NIH under a Cooperative Research and Development Agreement (CRADA) and is expected to initiate mid-year 2023.

Key Points: 
  • The study will be conducted and funded by the NIH under a Cooperative Research and Development Agreement (CRADA) and is expected to initiate mid-year 2023.
  • “Disc now has ongoing development programs of bitopertin in both erythropoietic porphyria and DBA.
  • The phase 2 study will be a pilot, single-arm, dose-escalation trial of bitopertin in DBA patients who either have steroid-refractory and/or relapsed disease or are unable to tolerate systemic corticosteroids.
  • Upon completion of the main treatment period, patients may continue on extended treatment within the trial.

FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS

Retrieved on: 
Monday, December 12, 2022
Heme, Therapy, DLBCL, Lymphatic system, Immune system, PBD, Society, Biomarker, Patient, Cancer, ADC, Research, Biology, NYSE, Diffuse large B-cell lymphoma, FDA, Molecular biology, Nucleic acid thermodynamics, Multimedia, Loncastuximab tesirine, Control, SAN, Blood, Machine learning, ASH, Hodgkin lymphoma, Medical imaging, Fine chemical, Pharmaceutical industry, San Francisco Bay Area, Catriona lonca, Camisole

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The findings presented at ASH show promise in identifying biomarkers associated with response to lonca and also suggested mechanisms of resistance seen in non-responders, which may inform future drug combination research.
  • "We look forward to further exploration of these findings to determine their significance for healthcare providers trying to identify the most appropriate treatments for patients with DLBCL."
  • "ADC Therapeutics is a leader in the field of antibody-drug conjugates," said Mike Nolan , chief executive officer, Freenome.
  • The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Key Impossible Foods Patent Revoked in Europe; Additional Challenges Filed in U.S.

Retrieved on: 
Wednesday, December 7, 2022
Heme, Union, EPO, Smell, European Patent Convention, Sulfur, Meat, Motif, Invention, Sugar, Joint, Impossible Foods, Impossible, Taste, European Patent Office, Patent, Generic drug, Food preservation, Pharmaceutical industry, EU

BOSTON, Dec. 7, 2022 /PRNewswire/ -- The Opposition Division of the European Patent Office ("EPO") recently announced that it has revoked a key Impossible Foods' European Union patent, No.

Key Points: 
  • BOSTON, Dec. 7, 2022 /PRNewswire/ -- The Opposition Division of the European Patent Office ("EPO") recently announced that it has revoked a key Impossible Foods' European Union patent, No.
  • At the same time, Motif FoodWorks , the Boston-based company making plant-based food better tasting and more nutritious, today announced the filing of four additional challenges to U.S. patents held by Impossible Foods.
  • "At the same time, we continue to challenge additional Impossible patents in the U.S. that also limit plant-based innovation and consumer choice."
  • Motif has filed four new petitions with the U.S. patent office to challenge the validity of these patents.

CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina

Retrieved on: 
Friday, September 2, 2022
Oncology, Health, Stem Cells, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Research Triangle Park, CAR, RTP, CGMP, Board, Hotel des Indes (The Hague), Heme, CMC, Health Canada, Multimedia, PRIME, GMP, Company, FDA, Minister of Health (Canada), Patient, Â, Vaccine, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220902005075/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220902005075/en/
    CARsgen's RTP GMP Manufacturing Facility (Photo: Business Wire)
    The RTP GMP Manufacturing Facility, with a total gross floor area of approximately 3,300 sq.m, will provide CARsgen additional manufacturing capacity of autologous CAR T-cell products for 700 patients annually to support clinical studies and early commercial launch in North America and Europe.
  • I am very pleased to announce that the RTP Manufacturing Facility has achieved the companys target of releasing the clinical batches for the U.S. patient use in Q3, 2022, said Mr. Richard Daly, President of CARsgen Therapeutics Corporation.
  • The company will accelerate the ongoing clinical studies by providing more promising CAR T-cell products to the global patients.
  • The commencement of clinical production at the RTP GMP Manufacturing Facility will greatly reduce current risks of global supply chain shortage and strengthen the value chain of CARsgen.

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs Development Report 2022: 21 Molecules with Approximately 15 Molecules Developed by Companies, Remaining by Universities - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Pharmaceutical, Health, Molecule, Discovery, R, Therapy, Heme, Cerebellar ataxia, Mall of America, FXN, Protein, Cardiomyopathy, SEC, Central nervous system, EC, Fine chemical

The "Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • Frataxin Mitochondrial - Drugs In Development 2022 outlays comprehensive information on the Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Frataxin is a protein encoded by the FXN gene.
  • Furthermore, this report also reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics development with respective active and dormant or discontinued projects.